Chronic inflammation is not associated with attenuated sodium-glucose co-transporter 2 inhibitor-induced hemoglobin increase in patients with diabetes.

ABSTRACT:

Aims/introduction

This study aimed to investigate whether the use of sodium-glucose co-transporter 2 inhibitors (SGLT2is) is associated with an increase in hemoglobin in the presence of chronic inflammation.

Materials and methods

This is a matched-pair cohort study. Patients with diabetes who visited outpatient clinics from 2019 to 2023 were enrolled. New users and never-users of SGLT2is were matched by propensity scores, separately for those with C-reactive protein (CRP) levels lower than and higher than the median time-averaged CRP. Hemoglobin levels at the last visit for given estimated glomerular filtration rates (eGFR) were estimated using robust regression models with cubic terms of eGFR as covariates. Changes in hemoglobin, CRP, and mean corpuscular volume (MCV) were

SUBMITTER: Murashima M 

PROVIDER: S-EPMC12757674 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature